{"doi":"10.1128/aac.42.10.2542","title":"Efficacies of KY62 against\n            <i>Leishmania amazonensis</i>\n            and\n            <i>Leishmania donovani</i>\n            in Experimental Murine Cutaneous Leishmaniasis and Visceral Leishmaniasis","abstract":"<jats:title>ABSTRACT</jats:title>\n          <jats:p>\n            Current therapy for leishmaniasis is unsatisfactory because parenteral antimonial salts and pentamidine are associated with significant toxicity and failure rates. We examined the efficacy of KY62, a new, water-soluble, polyene antifungal, against cutaneous infection with\n            <jats:italic>Leishmania amazonensis</jats:italic>\n            and against visceral infection with\n            <jats:italic>Leishmania donovani</jats:italic>\n            in susceptible BALB/c mice. Mice were infected with\n            <jats:italic>L. amazonensis</jats:italic>\n            promastigotes in the ear pinna and in the tail and were treated with KY62 or amphotericin B. The cutaneous lesions showed a remarkable response to therapy with KY62 at a dose of 30 mg per kg of body weight per day. At this dose, the efficacy of KY62 was equivalent to or better than that of amphotericin B at 1 to 5 mg/kg/day. Mice infected intravenously with 10\n            <jats:sup>7</jats:sup>\n            <jats:italic>L. donovani</jats:italic>\n            promastigotes and treated with KY62 showed a 4-log reduction in the parasite burden in the liver and spleen compared to untreated mice. These studies indicate potent activity of KY62 against experimental cutaneous leishmaniasis caused by\n            <jats:italic>L. amazoniensis</jats:italic>\n            and against experimental visceral leishmaniasis caused by\n            <jats:italic>L. donovani</jats:italic>\n            .\n          </jats:p>","journal":"Antimicrobial Agents and Chemotherapy","year":1998,"id":614399,"datarank":0.47032413238937254,"base_score":3.1354942159291497,"endowment":3.1354942159291497,"self_citation_contribution":0.47032413238937254,"citation_network_contribution":0.0,"self_endowment_contribution":0.47032413238937254,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":22,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1583213,"name":"John R. Graybill","orcid":null,"position":1,"is_corresponding":false},{"id":1583215,"name":"Rosie Bocanegra","orcid":null,"position":2,"is_corresponding":false},{"id":1583216,"name":"Laura Najvar","orcid":null,"position":3,"is_corresponding":false},{"id":1583217,"name":"Eleanor Montalbo","orcid":null,"position":4,"is_corresponding":false},{"id":604480,"name":"Steven L. Regen","orcid":"0000-0001-6192-7916","position":5,"is_corresponding":false},{"id":526711,"name":"Peter C. Melby","orcid":"0000-0001-7320-7406","position":6,"is_corresponding":false},{"id":1583211,"name":"Hail M. Al-Abdely","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Efficacies of KY62 against\n            <i>Leishmania amazonensis</i>\n            and\n            <i>Leishmania donovani</i>\n            in Experimental Murine Cutaneous Leishmaniasis and Visceral Leishmaniasis","abstract":"<jats:title>ABSTRACT</jats:title>\n          <jats:p>\n            Current therapy for leishmaniasis is unsatisfactory because parenteral antimonial salts and pentamidine are associated with significant toxicity and failure rates. We examined the efficacy of KY62, a new, water-soluble, polyene antifungal, against cutaneous infection with\n            <jats:italic>Leishmania amazonensis</jats:italic>\n            and against visceral infection with\n            <jats:italic>Leishmania donovani</jats:italic>\n            in susceptible BALB/c mice. Mice were infected with\n            <jats:italic>L. amazonensis</jats:italic>\n            promastigotes in the ear pinna and in the tail and were treated with KY62 or amphotericin B. The cutaneous lesions showed a remarkable response to therapy with KY62 at a dose of 30 mg per kg of body weight per day. At this dose, the efficacy of KY62 was equivalent to or better than that of amphotericin B at 1 to 5 mg/kg/day. Mice infected intravenously with 10\n            <jats:sup>7</jats:sup>\n            <jats:italic>L. donovani</jats:italic>\n            promastigotes and treated with KY62 showed a 4-log reduction in the parasite burden in the liver and spleen compared to untreated mice. These studies indicate potent activity of KY62 against experimental cutaneous leishmaniasis caused by\n            <jats:italic>L. amazoniensis</jats:italic>\n            and against experimental visceral leishmaniasis caused by\n            <jats:italic>L. donovani</jats:italic>\n            .\n          </jats:p>","is_dataset_classified":null,"base_score":3.1354942159291497,"endowment":3.1354942159291497,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"9756753","pmcid":"PMC105886","openalex_id":"https://openalex.org/W2171833596","authors":[],"funders":[{"funder_name":"NIAID NIH HHS","grant_id":"AI28220","title":null}],"total_grants":1,"fwci":2.5978,"citation_percentile":0.89723633,"influential_citations":0,"citation_trend":[{"year":2016,"count":2},{"year":2017,"count":2},{"year":2019,"count":1},{"year":2020,"count":2},{"year":2026,"count":1}],"oa_status":"bronze","license":"https://journals.asm.org/non-commercial-tdm-license","oa_locations":[{"url":"https://aac.asm.org/content/aac/42/10/2542.full.pdf","host_type":"journal"},{"url":"https://aac.asm.org/content/aac/42/10/2542.full.pdf","host_type":"publisher"},{"url":"https://journals.asm.org/doi/pdf/10.1128/AAC.42.10.2542","host_type":"publisher"},{"url":"https://doi.org/10.1128/aac.42.10.2542","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/9756753","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/105886","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC105886/pdf/ac002542.pdf","host_type":"repository"}],"fields_of_study":["Research on Leishmaniasis Studies","Trypanosoma species research and implications","Eosinophilic Disorders and Syndromes","Amphotericin B","Animals","Antifungal Agents","Female","Leishmania donovani","Leishmania mexicana","Leishmaniasis, Cutaneous","Leishmaniasis, Visceral","Mice","Mice, Inbred BALB C"],"mesh_terms":["Amphotericin B","Animals","Antifungal Agents","Female","Leishmania donovani","Leishmania mexicana","Leishmaniasis, Visceral","Mice, Inbred BALB C","Leishmaniasis, Cutaneous","Mice"],"keywords":["Visceral leishmaniasis","Leishmania donovani","Leishmaniasis","Amphotericin B","Pentamidine","Cutaneous leishmaniasis","Leishmania","Biology","Immunology","Pharmacology","Leishmania mexicana","Microbiology","Medicine","Parasite hosting","Internal medicine","Antifungal","Pneumonia"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T13:05:01.832860Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}